One Capital Management LLC Has $3.80 Million Stock Holdings in Guardant Health, Inc. $GH

One Capital Management LLC boosted its holdings in Guardant Health, Inc. (NASDAQ:GH) by 17.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 37,181 shares of the company’s stock after acquiring an additional 5,541 shares during the quarter. One Capital Management LLC’s holdings in Guardant Health were worth $3,798,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in GH. Alyeska Investment Group L.P. bought a new position in Guardant Health in the 3rd quarter valued at about $114,421,000. Norges Bank bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $128,499,000. Franklin Resources Inc. raised its holdings in shares of Guardant Health by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock worth $182,836,000 after purchasing an additional 606,368 shares during the period. Qube Research & Technologies Ltd grew its stake in Guardant Health by 124.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 570,095 shares of the company’s stock valued at $35,620,000 after buying an additional 315,896 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Guardant Health by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after buying an additional 277,001 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on GH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Guggenheim lowered shares of Guardant Health from a “buy” rating to a “buy” rating in a research report on Thursday, May 28th. BTIG Research set a $160.00 target price on shares of Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, May 27th. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Finally, Stifel Nicolaus upped their price objective on shares of Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Twenty equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Guardant Health currently has an average rating of “Moderate Buy” and an average target price of $136.37.

Insiders Place Their Bets

In other Guardant Health news, CEO Amirali Talasaz sold 210,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total value of $23,076,900.00. Following the sale, the chief executive officer owned 1,886,504 shares in the company, valued at approximately $207,307,924.56. This represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John G. Saia sold 10,000 shares of the company’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $125.08, for a total transaction of $1,250,800.00. Following the completion of the sale, the insider owned 35,950 shares in the company, valued at approximately $4,496,626. This trade represents a 21.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 332,244 shares of company stock valued at $36,156,026. Insiders own 5.60% of the company’s stock.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $130.17 on Wednesday. The stock has a market capitalization of $17.26 billion, a P/E ratio of -38.40 and a beta of 1.61. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $133.97. The company’s 50-day moving average is $95.88 and its 200 day moving average is $100.18.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.